Novel and Combination Therapies for Hepatitis C Virus, An Issue of Clinics in Liver Disease PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Novel and Combination Therapies for Hepatitis C Virus, An Issue of Clinics in Liver Disease PDF full book. Access full book title Novel and Combination Therapies for Hepatitis C Virus, An Issue of Clinics in Liver Disease by Paul J. Pockros. Download full books in PDF and EPUB format.
Author: Paul J. Pockros
Publisher: Elsevier Health Sciences
ISBN: 1455771988
Category : Medical
Languages : en
Pages : 245
Get Book Here
Book Description
Dr. Pockros has created a clinically focused issue based on the CONO 2012 meeting, whereby he was able to have those presenters write articles for his issue. Therefore, the content for HCV in this issue reflects the most current knowledge. The issue is focused on basic/current information, current therapy and special populations, triple and quad combination therapies in development, and an article on second generation protease inhibitors. The reader can expect that this issue will provide thorough clinical reviews on the most current therapeutic options for HCV.
Author: Paul J. Pockros
Publisher: Elsevier Health Sciences
ISBN: 1455771988
Category : Medical
Languages : en
Pages : 245
Get Book Here
Book Description
Dr. Pockros has created a clinically focused issue based on the CONO 2012 meeting, whereby he was able to have those presenters write articles for his issue. Therefore, the content for HCV in this issue reflects the most current knowledge. The issue is focused on basic/current information, current therapy and special populations, triple and quad combination therapies in development, and an article on second generation protease inhibitors. The reader can expect that this issue will provide thorough clinical reviews on the most current therapeutic options for HCV.
Author: Paul J. Pockros
Publisher: Clinics: Internal Medicine
ISBN: 9781455771127
Category : Medical
Languages : en
Pages : 0
Get Book Here
Book Description
Dr. Pockros has created a clinically focused issue based on the CONO 2012 meeting, whereby he was able to have those presenters write articles for his issue. Therefore, the content for HCV in this issue reflects the most current knowledge. The issue is focused on basic/current information, current therapy and special populations, triple and quad combination therapies in development, and an article on second generation protease inhibitors. The reader can expect that this issue will provide thorough clinical reviews on the most current therapeutic options for HCV.
Author: Paul J. Pockros
Publisher: Saunders
ISBN: 9781437712360
Category : Medical
Languages : en
Pages : 0
Get Book Here
Book Description
The Guest Editor presents state-of-the-art articles devoted to therapies for treatment of HCV. The novel therapies addressed in this issue include interferons, viral kinetics and anti-viral resistence, anti-fibrotics, immunotherapeutics, hepatoprotectants and caspace inhibitors, and cyclosporine analogues, to name a few.
Author: Barbara McGovern
Publisher: Elsevier Health Sciences
ISBN: 145574719X
Category : Medical
Languages : en
Pages : 240
Get Book Here
Book Description
Hepatitis C infection can be an acute or chronic illness and is the most common cause of liver disease in the US. It often goes undiagnosed until significant organ damage has occurred. This issue of the ID Clinics discusses the staging of liver disease, treatments for those newly diagnosed, and those who are dealing with chronic illness, along with managing drug therapy and virus resistance.
Author: National Academies of Sciences, Engineering, and Medicine
Publisher: National Academies Press
ISBN: 0309438020
Category : Medical
Languages : en
Pages : 187
Get Book Here
Book Description
Hepatitis B and C cause most cases of hepatitis in the United States and the world. The two diseases account for about a million deaths a year and 78 percent of world's hepatocellular carcinoma and more than half of all fatal cirrhosis. In 2013 viral hepatitis, of which hepatitis B virus (HBV) and hepatitis C virus (HCV) are the most common types, surpassed HIV and AIDS to become the seventh leading cause of death worldwide. The world now has the tools to prevent hepatitis B and cure hepatitis C. Perfect vaccination could eradicate HBV, but it would take two generations at least. In the meantime, there is no cure for the millions of people already infected. Conversely, there is no vaccine for HCV, but new direct-acting antivirals can cure 95 percent of chronic infections, though these drugs are unlikely to reach all chronically-infected people anytime soon. This report, the first of two, examines the feasibility of hepatitis B and C elimination in the United States and identifies critical success factors. The phase two report will outline a strategy for meeting the elimination goals discussed in this report.
Author: Naglaa Allam
Publisher: BoD – Books on Demand
ISBN: 9535129937
Category : Medical
Languages : en
Pages : 408
Get Book Here
Book Description
As in many areas of medicine, treatment of viral hepatitis has seen an acceleration of change driven by new therapies and evolving technology. Thanks to the direct-acting antiviral agents (DAAs), the era of HCV eradication and cure has begun. As regards to hepatitis B therapy, potent antiviral drugs for suppression of viral replication are available, new research activities to enhance eradication are visible, and these may influence clinical practice in the coming years. This book covers the latest advances in hepatitis C and hepatitis B therapeutics as well as the emerging and investigational treatment strategies. "Advances in Treatment of Hepatitis C and Hepatitis B" book is an up-to-date source of information for physicians, residents, and advanced medical students seeking a broader understanding of treatment of viral hepatitis. The authors of the chapters come from many eminent centers around the world and are experts in their respective fields.
Author: K. Rajender Reddy
Publisher: Elsevier Health Sciences
ISBN: 0323402496
Category : Medical
Languages : en
Pages : 249
Get Book Here
Book Description
There are over 180 million people with chronic HCV infection worldwide with between 2.7 and 3.9 million in the United States. Hepatitis C most significantly affects Asia and Africa, with rates up to 15% in countries such as Egypt and up to 30% in certain regions such as Punjab, Pakistan. Hepatitis C places a significant burden on the public health infrastructure, as it remains the leading cause of chronic liver disease, accounting for 50-75% of primary liver cancers and is responsible for 30% of all liver transplantations. It is estimated to have cost the United States $5.5 billion in 1997, comparable to the national cost of asthma, $5.8 billion in 1994.This number is only expected to grow as the current HCV population ages, increasing overall rates of compensated cirrhosis/end-stage liver disease. The evolution of directly acting anti-virals has ushered in a new era for chronic hepatitis C. Ongoing drug development strategy has involved targeting several replication steps of the virus and the hope is to see all oral therapies by late 2014 or early 2015. Thus we are at an exciting cross roads with regard to new information and challenges with HCV: rising disease burden with associated high costs, the challenges globally and in multiple patient populations, and the impending availability of effective and well tolerated treatments. Therefore there is a need to commission an exclusive issue of GCNA for HCV.
Author: Institute of Medicine
Publisher: National Academies Press
ISBN: 0309146283
Category : Medical
Languages : en
Pages : 252
Get Book Here
Book Description
The global epidemic of hepatitis B and C is a serious public health problem. Hepatitis B and C are the major causes of chronic liver disease and liver cancer in the world. In the next 10 years, 150,000 people in the United States will die from liver disease or liver cancer associated with chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infections. Today, between 800,000 and 1.4 million people in the United States have chronic hepatitis B and between 2.7 and 3.9 million have chronic hepatitis C. People most at risk for hepatitis B and C often are the least likely to have access to medical services. Reducing the rates of illness and death associated with these diseases will require greater awareness and knowledge among health care workers, improved identification of at-risk people, and improved access to medical care. Hepatitis B is a vaccine-preventable disease. Although federal public health officials recommend that all newborns, children, and at-risk adults receive the vaccine, about 46,000 new acute cases of the HBV infection emerge each year, including 1,000 in infants who acquire the infection during birth from their HBV-positive mothers. Unfortunately, there is no vaccine for hepatitis C, which is transmitted by direct exposure to infectious blood. Hepatitis and Liver Cancer identifies missed opportunities related to the prevention and control of HBV and HCV infections. The book presents ways to reduce the numbers of new HBV and HCV infections and the morbidity and mortality related to chronic viral hepatitis. It identifies priorities for research, policy, and action geared toward federal, state, and local public health officials, stakeholder, and advocacy groups and professional organizations.
Author: World Health Organization
Publisher: World Health Organization
ISBN: 9789241549981
Category : Medical
Languages : en
Pages : 0
Get Book Here
Book Description
Testing and diagnosis of hepatitis B (HBV) and C (HCV) infection is the gateway for access to both prevention and treatment services, and is a crucial component of an effective response to the hepatitis epidemic. Early identification of persons with chronic HBV or HCV infection enables them to receive the necessary care and treatment to prevent or delay progression of liver disease. Testing also provides an opportunity to link people to interventions to reduce transmission, through counselling on risk behaviors and provision of prevention commodities (such as sterile needles and syringes) and hepatitis B vaccination. These are the first WHO guidelines on testing for chronic HBV and HCV infection and complement published guidance by WHO on the prevention, care and treatment of chronic hepatitis C and hepatitis B infection. These guidelines outline the public health approach to strengthening and expanding current testing practices for HBV and HCV, and are intended for use across age groups and populations.
Author: Pere Ginès
Publisher: Springer Science & Business Media
ISBN: 1607618664
Category : Medical
Languages : en
Pages : 583
Get Book Here
Book Description
Chronic liver failure is a frequent condition in clinical practice that encompasses all manifestations of patients with end-stage liver diseases. Chronic liver failure is a multiorgan syndrome that affects the liver, kidneys, brain, heart, lungs, adrenal glands, and vascular, coagulation, and immune systems. Chronic Liver Failure: Mechanisms and Management covers for the first time all aspects of chronic liver failure in a single book, from pathogenesis to current management. Each chapter is written by a worldwide known expert in their area and all provide the latest state-of-the-art knowledge. This volume is specifically designed to provide answers to clinical questions to all doctors dealing with patients with liver diseases, not only clinical gastroenterologists and hepatologists, but also to internists, nephrologists, intensive care physicians, and transplant surgeons.
